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Although our current knowledge of the pathophysiology of COVID-19 is still fragmentary, the information so far
accrued on the tropism and life cycle of its etiological agent SARS-CoV-2, together with the emerging clinical data,
suffice to indicate that the severe acute pulmonary syndrome is the main, but not the only manifestation of
COVID-19. Necropsy studies are increasingly revealing underlying endothelial vasculopathies in the form of
micro-haemorrhages and micro-thrombi. Intertwined with defective antiviral responses, dysregulated coagulation
mechanisms, abnormal hyper-inflammatory reactions and responses, COVID-19 is disclosing a wide pathophys-
iological palette. An additional property in categorising the disease is the combination of tissue (e.g. neuro- and
vasculo-tropism) with organ tropism, whereby the virus preferentially attacks certain organs with highly devel-
oped capillary beds, such as the lungs, gastrointestinal tract, kidney and brain. These multiple clinical pre-
sentations confirm that the acute respiratory syndrome as described initially is increasingly unfolding as a more
complex nosological entity, a multiorgan syndrome of systemic breadth. The neurological manifestations of
COVID-19, the focus of this review, reflect this manifold nature of the disease.1. Introduction
Due to a multiplicity of factors including the presenting symptom-
atology and the kindredness of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) with other related coronaviruses (CoVs) like
severe acute respiratory syndrome CoV (SARS-CoV) and the Middle East
respiratory syndrome CoV (MERS-CoV), the CoV disease 2019 (COVID-
19) was initially categorized as severe pneumonia (Sun et al., 2020).
Most cases of the disease, especially those admitted to intensive care
units (ICUs), were diagnosed, and treated as such (Wang et al., 2020a;
Zhou et al., 2020a; Arentz et al., 2020; Chen et al., 2020a; Jain and Yuan,
2020). The categorization of severity -mild, not requiring respiratory aid;
moderate, requiring some form of respiratory assistance; and severe,
requiring obligatory mechanical respiratory support-was also dominated
by the pulmonary pathology and respiratory dysfunction (Mao et al.,
2020). However, as we learn more about the new viral disease, limiting it
to a severe acute respiratory syndrome has proved to be neither an ac-
curate not a comprehensive description of this nosological entity. Coro-
naviruses (CoVs) as a family cause respiratory, gastrointestinal,
nephrological, and neurological disease, but SARS-CoV-2 can adopt any
of these manifestations and several more.
As the pandemic enters its second year, the evolution of the diseasem 23 March 2021; Accepted 28 M
is an open access article under thas given rise to additional clinical forms associated with long-term
chronic variants of the disease (post-COVID-19 syndrome, long COVID-
19, long-haulers) (Antonini, 2020; Baig, 2020; Heneka et al., 2020;
Fotuhi et al., 2020), thus blurring the initial circumscription of COVID-19
to an acute syndrome, as the acronym of its causative agent conveys. The
persistence of the disease can be manifest as lingering symptoms (e.g.
dysosmias persisting for months) or as new symptoms not present during
the acute phase (e.g. confusion, memory loss). In a study conducted on
478 COVID-19 patients 4 months after hospital discharge, 51% had at
least one new symptom: 31% fatigue, 21% cognitive symptoms and 16
new-onset dyspnoea (Group TWCftCS, 2021).
Undoubtedly the most important sequelae of the long-term and
chronic forms of the disease are of a psychological and neuropsychiatric
nature and are already being manifested in the increased incidence
among COVID-19 patients in the mid- and long-term post-infective
phases of the disease (Rogers et al., 2020). Psychological burnout,
“pandemic fatigue” and in more severe cases post-critical illness or
post-traumatic chronic stress syndrome (PTSD) are affecting an alarming
number of patients. PTSD has been associated with the depression of the
immune system that may follow acute exacerbated immune responses
(Liang et al., 2020a). An early study of 714 clinically stable
post-COVID-19 patients indicated that 96.2% of them suffered fromarch 2021
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An additional group of post-acute COVID-19 patients consists of
persistently infected but asymptomatic and pre-symptomatic carriers
(Rasmussen and Popescu, 2021) and patients with only mild symptoms.
The former set of patients constitutes an important source of contagion
(see recent review in (Gao et al., 2021)) which is difficult to assess from
an epidemiological viewpoint. Asymptomatic carriage has been coined
the Achilles’ heel of COVID-19 control strategies (Gandhi et al., 2020).
Immunocompromised patients are another source of contagion, shedding
virions for several months after remission of the acute phase of the dis-
ease (Avanzato et al., 2020). Millions of immunosuppressed patients
suffering acquired immunodeficiency syndrome (~26 million in Africa
alone) and tuberculosis are at risk of contracting severe forms of
COVID-19.
Reviews and literature meta-analyses on the neurological aspects of
COVID-19 (Berger, 2020; Zubair et al., 2020; De Felice et al., 2020;
Montalvan et al., 2020; Gklinos, 2020; Leonardi et al., 2020; Vonck et al.,
2020) point to two types of neurological affectation, namely
para-infectious and post-infectious sequelae, and three main pathogenic
mechanisms of central nervous system (CNS) affectation in COVID-19,
with some possible overlap: a) direct primary damage of the CNS pa-
renchyma, a rare occurrence; b) hyper-inflammatory response syndrome
(cytokine release syndrome, “cytokine storm”), mostly observed in se-
vere forms of COVID-19, overemphasized during the initial months of the
pandemic but statistically not a frequent occurrence either according to
ref (Mudd et al., 2020) and c) systemic sepsis, which may evolve to
complications like viral encephalitis or viral encephalopathy, and death.
I have recently discussed the current knowledge of the SARS-CoV-2
structure and biology with a view to developing prophylactic or thera-
peutic drugs (Barrantes, 2020a) and some entry points and routes fol-
lowed by the virus to produce pathogenic effects on the nervous system
(Barrantes, 2020b). In addition to the bronchopulmonary epithelium,
two important primary sources are the nasal and the intestinal mucosae,
because of the anatomical vicinity to the forebrain of the former and the
extensive surface and hence greater capacity to produce massive repli-
cation and release of virions into the bloodstream of the latter. In this
review I critically examine possible pathophysiological scenarios un-
derlying the neurological manifestation of the disease. To do so I exploit
the still fragmentary knowledge so far gained on SARS-CoV-2, focusing
on the direct and indirect pathogenic mechanisms exerted by the virus on
the endothelial cell and on the intestinal tract-CNS connection.
The reader is referred to recent reviews on COVID-19 general clinical
aspects (Richardson et al., 2020; Guan et al., 2020), endocrinological
features (Stefan et al., 2021), neuropsychiatric aspects (Rogers et al.,
2020; Alonso-Lana et al., 2020; Wang et al., 2021a, 2021b),
brain-immune axis of the disease (Wang et al., 2021b; Peters et al., 2021),
drug repurposing ((Barrantes, 2020a; Cavasotto and Di Filippo, 2021)
microbiology (Fung and Liu, 2019) and epidemiology (Su et al., 2016) of
Coronaviruses, and of SARS-CoV-2 biology and evolutionary aspects (Li
et al., 2020a) or physicochemical aspect impinging on airborne trans-
mission of the virus (Scheller et al., 2020).
2. Evolution of the COVID-19 clinical and neurological picture
Typical reports of COVID-19 presentation among individuals
admitted to hospital during the initial months of the pandemic included
lower respiratory tract infection and fever, dry cough, and dyspnoea
(Huang et al., 2020). Fever is still the most frequent sign, observed in up
to 90% of patients (Guan et al., 2020), followed by bilateral lung infil-
tration with ground-glass opacity (50%) in thoracic CT scans, and lym-
phopenia, a possible consequence of the combination of T lymphocyte
destruction by the virus and hampered lymphopoiesis (Wang et al.,
2020a; Guan et al., 2020). But in addition to the dominant pulmonary
affectation, other clinical manifestations reflecting involvement of other
organs have become progressively apparent. Gastrointestinal (Jin et al.,
2020; Parasa et al., 2020; Zhou et al., 2020b; Ding and Liang, 2020),2
multi-organ thrombotic and thromboembolic disease (Bikdeli et al.,
2020) (Jain and Yuan, 2020), and sepsis with microcirculatory
compromise (Colantuoni et al., 2020; Magro et al., 2020) were rapidly
added to the predominant respiratory syndrome. Detailed accounts of the
respiratory affectation and other clinical aspect of the disease can be
found in recent reviews (Richardson et al., 2020; Guan et al., 2020; del
Rio and Malani, 2020; Wiersinga et al., 2020).
The neurological compromise in COVID-19 patients was already
described in early studies: of 214 COVID-19 patients 36.4% presented
neurological symptoms (Mao et al., 2020). A similar study found that
36% of patients reported CNS symptoms (impaired consciousness) and
peripheral symptoms (e.g. paraesthesias) (Wu et al., 2020a). A larger
study (1099 patients) described other neurological manifestations like
myalgias (14.9%) and headache (13.6%) (Guan et al., 2020). One of the
first European studies found a higher percentage (57.4%) of neurological
manifestations among 841 Spanish COVID-19 patients, predominantly
male, with myalgias and headaches as main symptoms (Romero-Sanchez
et al., 2020). Myopathies with elevated creatine kinase levels and axonal
polyneuropathies had already been described for SARS patients 2–4
weeks into the course of the virosis (Tsai et al., 2004, 2005). In
COVID-19, a reported case of myopathy with high creatine kinase levels
was found to be a type I interferonopathy in response to SARS-CoV-2
infection (Manzano et al., 2020). Rhabdomyolysis, Guillain-Barre syn-
drome (De Felice et al., 2020; Wu et al., 2020a; Carod-Artal, 2020;
Pleasure et al., 2020) and myoclonus (Rabano-Suarez et al., 2020) have
also been reported. Unlike the syndrome caused by other viruses that
induce demyelinating forms of Guillain-Barre, COVID-19 is associated
with axonal or sensory pathologies. Importantly, it became apparent that
the type of neurological presentations in COVID-19 patients was associ-
ated with the severity of the disease; stroke, seizures, ataxia, depressed
consciousness and myopathies occur more frequently in the severe forms
(45.5%) than in the less severe forms (30.2%) (Mao et al., 2020) and
constitute in several cases life-threatening neurological complications of
the disease (Carod-Artal, 2020).
Neurodegenerative diseases and particularly Alzheimer disease and
Parkinson disease share some common clinical manifestations with
COVID-19: 1) dysosmias at early stages of Alzheimer disease (see liter-
ature meta-analysis in (Silva et al., 2018)) or both anosmia and dysgeusia
in Parkinson disease (Tarakad and Jankovic, 2017; Poewe et al., 2017;
Otero-Losada et al., 2020); 2) histopathological alterations of the olfac-
tory mucosa early on (Talamo et al., 1989) (Perry et al., 2003) and
subsequent degeneration of the olfactory bulb (Murphy et al., 1990) in
the course of both diseases, the latter progressing in parallel with the
evolution frommild cognitive impairment to full dementia (Bathini et al.,
2019). Pathophysiological findings of aggregated α-synuclein have been
tentatively associated with hyposmia in Parkinson disease (Poewe et al.,
2017). The possibility has recently been formulated that sustained
inflammation and increased levels of α-synuclein in the course of
COVID-19, as observed with West Nile virus and Western encephalitis
virus infections, leads to the formation of aggregates akin to those of
Parkinson disease (Brundin et al., 2020). Intensive research in the Alz-
heimer disease field has been devoted to developing strategies to deliver
putative therapeutic agents into the brain; e.g. intranasal application has
been used in these attempts to circumvent the blood-brain barrier (BBB)
in an effort to reduce systemic effects on other organs, avoid first-pass
hepatic metabolism, and exploit the higher bioavailability and faster
pharmacokinetics of the intransal route (Erd}o et al., 2018).
Cell-penetrating peptides have been employed to catalyse the
nasal-to-brain transport of macromolecules. Upon conjugation with a low
molecular weight protamine, administration of nanoparticles and pro-
teins into brain was shown to be facilitated by the conjugates (Lin et al.,
2016).
Parkinson disease as a neurological comorbidity was initially
considered a rare occurrence (Sulzer et al., 2020), but more recently
single-case reports indicate the development of (probably) progressive
parkinsonism 2–5 weeks after infection with SARS-CoV-2. In one such
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hypokinetic-rigid syndrome after severe COVID-19 (Mendez-Guerrero
et al., 2020). Two other cases also followed severe COVID-19 (Cohen
et al., 2020; Faber et al., 2020); the three patients showed brain imaging
manifestations of nigrostriatal dopamine system hypoactivity. Although
it cannot be established whether the SARS-CoV-2 infection acted as a
trigger or catalyser of the parkinsonism or is a mere coincidental
occurrence, the motor symptomatology is highly suggestive of a causa-
tive relationship (Brundin et al., 2020). Merello and coworkers discuss
three different scenarios of transient or permanent parkinsonism
following viral infections (Merello et al., 2020). The pathophysiology of
Parkinson disease associated with COVID-19 is still not clear, but
SARS-CoV-2 infection may trigger α-synuclein upregulation, followed by
immune reactions resulting from α-synuclein deposition; glial compro-
mise may ensue, further amplifying the immune response as a product of
cytokine and chemokine production by the microglia. Microglia cell
response is also known to be elicited by α-synuclein (Awogbindin et al.,
2020).
Cases of myasthenia gravis have been reported in association with
COVID-19 (Restivo et al., 2020; Finsterer et al., 2020), raising the pos-
sibility that autoimmune antibodies against SARS-CoV-2 epitopes might
also react against the nicotinic acetylcholine receptor or other molecular
constituents of the neuromuscular junction (Paz and Barrantes, 2019).
Patients with severe forms of COVID-19 and requiring ICU care are
more prone to develop multiple organ system dysfunction, presenting in
some cases complications of a neurological nature, such as ischemic and
cerebrovascular disease (Mao et al., 2020; Wu et al., 2020a; Li et al.,
2020b; Sharifi-Razavi et al., 2020; Pezzini and Padovani, 2020). Multi-
centre retrospective-prospective studies of neurological manifestations in
COVID-19 are beginning to appear (Ferrarese et al., 2020). This type of
study is needed to better ascertain the actual incidence of neurological
compromises in the viral disease on a more solid statistical basis.
Chronic immune dysregulation is often invoked as a factor that pre-
disposes patients with Down syndrome to be more vulnerable to pul-
monary infections and higher mortality rates from pneumonia and sepsis.
Thus trisomy 21 patients may exhibit a higher risk of developing severe
forms of COVID-19 in case of SARS-CoV-2 infection (Espinosa, 2020).
3. Mild neurological symptoms: dysosmias and dysgeusias
The hundreds to thousands of genes of odour receptors make the ol-
factory system unique among sensory systems (Brann and Datta, 2020).
Loss of smell (anosmia) and taste (dysgeusia) are by nowwell-established
early symptoms of COVID-19, although during the early months of the
pandemic these neurological symptoms were not necessarily associated
with the disease and were initially reported by otorhinolaryngologists
(Lüers et al., 2020). One of the earliest reports of dysosmias was the
finding of hyposmia among COVID-19 patients in Wuhan, China (Mao
et al., 2020). Of 10,069 patients studied in Tehran, Iran, 48.2% exhibited
anosmia or hyposmia, with abrupt installation of the anosmia in 76% of
the cases. Of these latter patients, 83.4% also exhibited dysgeusia
(Bagheri et al., 2020). Olfactory and gustatory disorders were also re-
ported in 34% of COVID-19 patients in Milan, Italy (Giacomelli et al.,
2020). A telephone survey in Treviso and Belluno provinces in Italy
analysed 202 individuals who tested positive for SARS-CoV-2; 64% re-
ported dysosmias or dysgeusias, more frequently among female patients,
and appearing before other symptoms in 12% of the cases (Spinato et al.,
2020). In Munich, Germany, in a study of 9 patients, 4 presented hypo-
smia, anosmia, dysgeusia or ageusia (W€olfel et al., 2020). A psycho-
physical study jointly undertaken on COVID-19 patients in 12 hospitals
across Europe showed a very high (~76%) incidence of these symptoms
and established correlations between olfactory and gustatory dysfunc-
tions, with dysosmias observed earlier than dysgeusias (Lechien et al.,
2020). As the pandemic passed the 6-month mark, anosmia and hypo-
smia appeared more frequently in otherwise asymptomatic (Boscolo-R-
izzo et al., 2020), mildly symptomatic (Spinato et al., 2020; Lechien et al.,3
2020), or as first-presenting symptoms (Boscolo-Rizzo et al., 2020; Lee
et al., 2020a; Gautier and Ravussin, 2020), or even as the only symptoms
(Hjelmesæth and Skaare, 2020). A statistical study performed in Teheran
subjected 60 confirmed COVID-19 patients and 60 matched control in-
dividuals to the Univ. of Pennsylvania Smell Identification Test (UPSIT),
a validated 40-odorant assay. Virtually all (98%) COVID-19 patients
tested positive for dysosmias: anosmia (25%), severe microsmia (33%),
moderate microsmia (27%), mild microsmia (13%) and one patient was
normosmic (2%) (Moein et al., 2020). One distinctive feature of the
dysosmias in COVID-19 is that they appear relatively early during the
disease, in contrast with what was observed in SARS. A second charac-
teristic is that they are seldom accompanied by rhinorrhoea.
In addition to the dysosmias, chemesthetic function (i.e. sensitivity to
chemical compounds like menthol or capsaicin in mucosae via peripheral
nociceptive receptors of somatosensory neuronal cells) was reduced
(37%) in the course of the disease (Parma et al., 2020). Qualitatively
distorted sensory perceptions like parosmias, or phantom chemosensory
perceptions like phatogeusias and phanthosmias were rarely observed.
The American Academy of Otolaryngology issued a statement warn-
ing that patients presenting this symptomatology in the absence of other
manifestations of respiratory disease such as allergic rhinitis, acute or
chronic rhinosinusitis, should be alert to the possibility of COVID-19
infection (Anosmia, Hyposmia, and Dysgeusia Symptoms of Coronavirus
Disease, https://www.entnet.org/content/coronavirus-disease-2019-res
ources (2020). Isolated sudden onset anosmia (ISOA) has been postu-
lated as a presentation syndrome of SARS-CoV-2 infection not accom-
panied by other symptoms in two case reports in which the individuals
tested positive for COVID-19 (Gane et al., 2020) (Eliezer et al., 2020); in
the latter case the anosmia was sudden and complete. A detailed quan-
titative study of dysosmias and dysgeusia can be found in ref. (Mercante
et al., 2020).
Some COVID-19 patients who recovered from severe pneumonia have
also referred long-term anosmia as a sequel of the disease and hyposmia,
remarkably, only seldom (Lüers et al., 2020; Carfì et al., 2020).
Long-lasting dysosmias are an infrequent presentation of SARS: there is a
case report of residual and severe form of anosmia in a female patient
infected with SARS-CoV about 3 weeks after onset of symptomatology
(Hwang, 2006). Post-viral disease olfactory loss appears to be associated
with a higher incidence of cranial neuropathies (Jitaroon et al., 2020).
Using an app launched in the UK to record symptoms of putative
COVID-19 infected persons through digital media, of ca. 1.5 million
surveyed individuals only 1702 had undergone an RT-PCR test: 579
tested positive. Of these, ca. 60% reported loss of smell and taste, leading
the authors to suggest that these symptoms are a strong predictor of
COVID-19 in non-tested individuals (Menni et al., 2020). Odour tests are
available for olfactionmemory dysfunctions (see e.g. (Frank andMurphy,
2020)) and are likely to be used more frequently to assess the degree of
olfactory sense loss and recovery in affected COVID-19 patients. A sta-
tistically significant correlation was found between the decrease in
interleukin-6 and recovery of smell after the olfactory dysfunction
episode (Cazzolla et al., 2020).
4. Invasion of the CNS
4.1. Transcriptomics of the mucosal epithelia
One of the rapidly growing areas of research in COVID-19 is that of
the virus-host cell interactome, aimed at identifying the proteins that
interact with the SARS-CoV-2 proteins and/or RNA. The genome of the
virus codes for about 28 proteins (4 structural proteins and 16 non-
structural proteins, nsps). The genes coding for the nsps are scattered
among the genes coding for the structural proteins in most CoVs (Fung
and Liu, 2019). The connectivity maps are complex, with sub-networks
and nodes involving between 330 and 400 possible interactions of
these 28 proteins with the many more host cell proteins and cellular
processes (Gordon et al., 2020a, 2020b; Díaz, 2020), including signalling
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RNA-host protein interactome also provides interesting therapeutic ap-
proaches (see review in (Schmidt et al., 2020)).
In a separate work I discuss transcriptomic studies disclosing the
topographical distribution and expression at the individual cell-type level
of angiotensin-converting enzyme 2 (ACE2) and its co-receptor trans-
membrane serine protease 2 (TMPRSS2) in the oral and nasal mucosae
and along the upper aerial respiratory track (Barrantes, 2020b). In brief,
and contrary to expectation, most studies report the absence of receptors
from the olfactory neuronal cells but abundant expression in goblet and
ciliated stem cells in the olfactory mucosa (Sungnak et al., 2020; Ziegler
et al., 2020), olfactory support cells and stem cells, and in vascular per-
icytes of the olfactory bulb (Chen et al., 2020b). A meta-analysis of
RNA-Seq libraries with ~29,000 single cells found ACE2/TMPRSS2
expression in sustentacular cells, and ACE2 alone in a subset of the sus-
tentacular cells in human olfactory neuroepithelium (Fodoulian et al.,
2020). Using a golden Syrian hamster model, the sustentacular cells were
shown to be the main target after intranasal SARS-CoV-2 instillation,
leading these authors to conclude that sustentacular cell injury suffices to
account for the dysfunctional odour perception (Bryche et al., 2020). The
death of sustentacular cells would deprive olfactory neurons of the cy-
tochrome P450 detoxifying activity and cilia that the former cells provide
(Bilinska and Butowt, 2020). All in all, the evidence appears to indicate
that SARS-CoV-2 exhibits tropism for various cell types in the olfactory
epithelium, leading to the death of sustentacular cells in a hamster
model, and possibly affecting several other cell types in humans.
SARS-CoV-2 may remain in the mucosa only and sustain the patho-
physiological effects in the periphery, accounting for the dysosmias, and
may utilize this entry point as they make their way to the CNS. Anato-
mopathological studies showing frontal cortex involvement and correl-
ative neuropsychiatric symptoms are already pointing in this direction
(Rogers et al., 2020; Kotfis et al., 2020).
4.2. The neural olfactory route
In animal model systems, the neurotropic herpes simplex virus type I
(HSVI) and mouse hepatitis virus (MHV) were early reported to enter the
CNS via olfactory neurons. After reaching the olfactory bulb, they spread
trans-neuronally along different neural pathways (Barnett et al., 1993).
Interestingly, the spread of the two viruses, infecting a unique and only
partially overlapping set of connections of the olfactory bulb, suggests a
marked tropism. Both viruses infected dopaminergic neurons in the
ventral tegmental area, but MHV produced a more widespread infection
in the A10 group, as well as infecting A8 and A9. In contrast, only HSV
infected noradrenergic neurons in the locus coeruleus. The results led the
authors to hypothesize that the differential pattern of viral spread could
be due to virus uptake by specific neurotransmitter systems, although
other factors could not be discarded, such as differences in the distribu-
tion of the synapses or the cellular receptor for the two viruses. See also
review by ref (van Riel et al., 2015) for a discussion of trans-synaptic viral
transport. Swine hemagglutinating encephalomyelitis virus also propa-
gates centripetally using a trans-synaptic pathway and causes deadly
acute encephalitis (Li et al., 2013). Bornavirus BoDV-1 is another virus
that reaches the CNS via the olfactory pathway (Sauder and Staeheli,
2003), as shown in vivo in adult rats and in vitro using olfactory mucosal
cell cultures (Kupke et al., 2019).
Other viruses that can use the nasal olfactory epithelium as entry
point and the olfactory nerve as a shortcut into the CNS include influenza
A virus, herpesviruses, poliovirus, paramyxoviruses, vesicular stomatitis
virus, rabies virus, parainfluenza virus, adenoviruses, Japanese enceph-
alitis virus, West Nile virus, chikungunya virus, La Crosse virus, mouse
hepatitis virus, and bunyaviruses (van Riel et al., 2015).
Among CoVs, hOC43-CoV has been reported to infect the CNS via the
nasal mucosa causing encephalitis with vacuolation in neuronal cells and
strong microglial reactivity in infected areas (Jacomy and Talbot, 2003).
In an animal model system, the hOC43-CoV apparently propagates from4
the nasal cavity to the olfactory bulb and piriform cortex to ultimately
reach the brain stem; in cell culture, an axonal neuron-to-neuron prop-
agation is followed (Dube et al., 2018).
4.3. The olfactory ensheathing cell route
The nasal mucosae have quite a variety of cells that viruses can
exploit, including the specialized olfactory-ensheathing glial cells of the
olfactory epithelium region. An additional route which to my knowledge
has not been contemplated for SARS-CoV-2 entry into the CNS is that
followed by some picornaviruses (among which are the common cold
rhinoviruses) and Bornaviruses. Picornavirus infection induces temporal
release of multiple extracellular vesicles, by which means they escape
control by their host cells and spread infection (van der Grein et al.,
2019). In the case of the Bornaviruses, which can cause fatal encephalitis
in humans, the study of Kupke et al. (2019) showed that viral antigens
were still present in the olfactory ensheathing cells four days after
infection with BoDV-1. This route could be operative upon infection of
any of the potential cell targets transiting along extracellular paths as
discussed in this review.
Instead of uptake by olfactory neurons and subsequent axonal trans-
port along the olfactory neural pathway, bypassing the extracellular
epithelial barrier appears to be the path chosen by small protein mole-
cules like the nerve growth factor (NGF). Upon intranasal administration
of 125I-labelled-NGF, the fast appearance of radioactive material is
observed in olfactory bulbs, brain, and brain stem (Frey et al., 1997).
4.4. The transmucosal aneural route
Alternative routes for CNS invasion by SARS-CoV-2 have been pro-
posed. The frequent alteration of smell associated with SARS-CoV-2
infection does not appear to be correlated with correspondingly
frequent neurological signs of infection of the olfactory bulb, olfactory
cortical areas, or rostral regions of the brain. As analysed above, dysos-
mias are an early symptom, and may appear in individuals otherwise
asymptomatic. It may well be that the infection is contained in the nasal
cavity. Locally, SARS-CoV infection leads to the disruption of the ciliated
epithelium and ciliary dyskinesia, which affect mucociliary clearance
and contribute distally to the pulmonary disease (Bustamante-Marin and
Ostrowski, 2017). Meinhardt and coworkers (Meinhardt et al., 2021)
demonstrated the presence of SARS-CoV-2 RNA and protein in anatom-
ically distinct regions of the nasopharynx and brain, (Meinhardt et al.,
2021). SARS-CoV-2 virions were found inside the cytoplasm of ciliated
cell and endothelial cells, where they disrupt kinocilia. SARS-CoV-2 can
subsequently enter the nervous system by crossing the neural–mucosal
interface, i.e. a transmucosal tract. Distinct thromboembolic ischemic
infarction lesions were found in brain.
5. SARS-CoV-2 receptors in brain
Even before the enzymes of the renin-angiotensin-aldosterone system
(RAAS) were identified in the CNS, it was known that infusion of
angiotensin II could increase blood pressure, and the presence of renin in
brain suggested that angiotensin could be synthesized locally (reviewed
in ref (Xu et al., 2011)). Early immunohistochemical work by the group of
Lazartigues identified the presence of ACE2 in neuronal cell bodies of rat
brain but not in glia (Doobay et al., 2007). These authors identified ACE2
positivity in the subfornical organ, and mRNA/protein expression was
found to be inversely correlated in the nucleus of the tractus solitar-
ius/dorsal motor nucleus of the vagus and the rostral ventrolateral me-
dulla oblongata. They further argued that the finding of ACE2 expression
in brain structures involved in the control of cardiovascular function
suggests that the enzyme may play a role in the central regulation of
blood pressure and autonomic nervous system diseases, such as hyper-
tension (Doobay et al., 2007). Expression of ACE2 was not only found in
the nucleus of the tractus solitarius but also in other areas associated with
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(Xia and Lazartigues, 2010). Interestingly, this occurrence of ACE in a
specialized group of CNS structures lacking a proper BBB, the so-called
circumventricular organs, may point to a direct route for SARS-CoV-2
to gain access to the brain from the general circulation. In addition, in-
puts to the circumventricular organs sense and integrate signals for fluid
balance (e.g. angiotensin II), metabolic control (e.g. leptin) and immune
regulation (e.g. IL-1β and IL-6) which, as we will see, play important roles
in COVID-19, and their outputs can directly influence individual CNS
neurons via efferent projections to autonomic control centres in the hy-
pothalamus and medulla (Ferguson et al., 2014).
Recent RNA-Seq studies have dissected the multiple CNS localizations
of ACE2mRNA, pointing to potential sites for SARS-CoV-2 binding. ACE2
has been found to be highly expressed in the substantia nigra, choroid
plexus and ventricles, olfactory bulb (Chen et al., 2020b) and various
cortical regions, including middle temporal gyrus, posterior cingulate
cortex, and frontal andmotor areas (Fig. 1). Another recent study showed
that ACE2 is widely expressed in vessels of different calibres in
post-mortem frontal cortex, and is significantly increased in the brain
vasculature of patients with a history of dementia or hypertension
(Buzhdygan et al., 2020). Interestingly, when the authors tested the effect
of the SARS-CoV-2 S1 protein subunit in an in vitro microfluidics model
system of the BBB, the spike protein induced a proinflammatory condi-
tion in the endothelial cells.
In vivo studies using human ACE2 transgenic mice and brain orga-
noids (“minibrains”) have disclosed the ability of SARS-CoV-2 to infect
neurons and cause their death (Song et al., 2020; Yang et al., 2020).
Dopaminergic neurons derived from human-induced pluripotent cells
appear to be particularly rich in ACE2, making them more vulnerable to
SARS-CoV-2 infection, whereas cortical neurons showed relatively low
expression levels of the enzyme (Yang et al., 2020). Electron microscope5
examination of a brain sample from a COVID-19 necropsy revealed
80–110 nm viral particles inside vesicles -presumably of endosomal na-
ture- in endothelial and neuronal cell bodies of the frontal cortex, a
finding that may correlate with the clinical picture of delirium observed
in some patients (Rogers et al., 2020; Kotfis et al., 2020; Kennedy et al.,
2020). The presence of the virus was evidenced also by RT-PCR of brain
tissue (Paniz-Mondolfi et al., 2020). In this single-case report, neuro-
psychiatric symptoms correlated with the post-mortem histology; during
hospitalization, the 74-year-old patient had episodes of confusion and
agitation and became combative, suggesting frontal cortex involvement.
SARS-CoV-2 RNA has also been found in a case of encephalopathy
(Moriguchi et al., 2020). A series of necropsies of 32 COVID-19 patients
showed (micro)thrombotic/thromboembolic signatures in the CNS and
olfactory mucosa. The latter regions exhibited 124% higher levels of
virion load than the lower respiratory tract (Meinhardt et al., 2021),
suggesting that SARS-CoV-2 may have used the nasal epithelium as entry
point and followed a centripetal route to reach the brain. Nuclear mag-
netic resonance bilateral signals compatible with viral infection were
observed in the two olfactory bulbs and the posterior gyrus rectus, a
cortical brain area associated with olfaction, in a COVID-19 patient
having symptoms of anosmia and dysgeusia (Politi et al., 2020).
6. Neurological complications and mortality among COVID-19
patients
SARS-CoV-2 is a highly pathogenic virus, and a non-negligible pro-
portion of COVID-19 patients experience deterioration of their physical
condition that often involves vital organs and can precipitate fatal out-
comes. About 15% of the COVID-19 patients evolve to a severe form of
the disease and 5–6% become critically ill (Wang et al., 2020a; Guan
et al., 2020; Huang et al., 2020). Non-neurological severe complicationsFig. 1. Distribution of ACE2 gene mRNA in adult
human brain regions. The illustration shows the
distribution of the SARS-CoV-2 host-cell receptor
using the probe ACE2-A_23_P252981 in a human
sample (patient HO351.2001). The dots display
the intensity of ACE2 mRNA expression in more
than 100 localizations including the telenceph-
alon, cerebral cortex, limbic lobe and hippocam-
pal formation in a sagittal view of the cortex (A,
solid representation; C, transparent rendering of
the cortical mass to enable visualization of the
internal structures (e.g. hippocampus, cerebellum
and brain stem) and rostro-caudal coronal view
enabling visualization of surface and internal
(midbrain) structures (B,D). The same visualiza-
tion protocol is followed: (B, solid representation;
D, transparent rendering of the cortical mass to
enable visualization of the internal structures).
The colour code reflects the intensity as high
(red), neutral (yellow) or low (blue). Obtained
from the Allen Human Protein Atlas (http://www
.proteinatlas.org) and the Human Brain Atlas
(http://human.brain-map.org) through Brain Ex-
plorer (https://human.brain-map.or
g/static/brainexplorer) (Hawrylycz et al., 2012).
(For interpretation of the references to colour in
this figure legend, the reader is referred to the
Web version of this article.)
F.J. Barrantes Brain, Behavior, & Immunity - Health 14 (2021) 100251of COVID-19 may lead to atypical acute respiratory syndrome, pulmo-
nary embolism, myocardial infarction, arterial or venous thrombosis of
any-calibre blood vessels, acute kidney failure or stroke (Wang et al.,
2020a; Zhou et al., 2020a; Arentz et al., 2020; Chen et al., 2020a; Jain
and Yuan, 2020; Piazza and Morrow, 2020). Older age and comorbidities
are among the main predictive factors of fatal outcomes (Zhou et al.,
2020a; Jain and Yuan, 2020; Wu et al., 2020b; Tang et al., 2020). Sta-
tistics of the risk scores predicting critical illness are beginning to
emerge. The retrospective analysis with the largest casuistic (72,314
individuals) indicates a case-fatality rate of 2.3% (Wu and McGoogan,
2020).
A study on 1590 patients hospitalized in China identified 10 variables
as independent predictive risk factors of neurological complications,
among which unconsciousness was the main neurological sign (Liang
et al., 2020b). Necropsies of SARS patients have also detected viral
particles in neuronal cell bodies in the cerebral cortex and hypothalamus
(Ding et al., 2003; Gu et al., 2005).
As the pandemic and the length of the recovery period of convalescent
patients extend in time, new aspects of the disease become apparent, such
as debilitating fatigue and gastrointestinal disarrays, or a constellation of
neuropsychological signs involving cognitive alterations and mental
exertion that resemble somemanifestations of myalgic encephalomyelitis
and/or chronic fatigue syndrome/PTSD, as observed in some survivors of
the 2013 SARS epidemic (Liang et al., 2020a; Tansey et al., 2007).
Statistically, the leading cause of death among hospitalized COVID-19
patients is an acute and atypical pneumonia, usually associated with an
overreactive inflammatory response. Respiratory failure was initially
reported as the main cause of death (69.5%) among 81 patients in Wuhan
(Zhang et al., 2020), with ARDS reported to be strongly associated with
mortality in severely ill COVID-19 patients (Yang and Jin, 2020). Pul-
monary arterial thrombosis of small and mid-sizes vessels has also been
reported as a cause of death (Lax et al., 2020). A recent meta-analysis
using an analytics platform (OpenSAFELY) covering 40% of all patients
in England (more than 17 million adults and ~11,000 COVID-19 pa-
tients) found that COVID-19-related deaths were statistically associated
with the following risk factors: older age, being male, obesity (Lockhart
and O’Rahilly, 2020) and its association with diabetes, severe forms of
asthma (Jackson et al., 2020), chronic respiratory disease, chronic heart
disease, autoimmune diseases and reduced kidney function among the
most salient comorbidities (Williamson et al., 2020). Black (Bunyavanich
et al., 2020; Rodgers and Gibbons, 2020) and South Asian people appear
to be at higher risk.
Although the pulmonary picture has dominated the characterization
of the disease, together with the atypical form ARDS appearing as a likely
terminal complication, obitus of COVID-19 patients may be due to
several other single-organ compromises (with heart, kidneys and brain
being highly susceptible to fatal failure) or, most plausibly, multi-organ
failure in severely ill patients. Remarkably, some of the most severe
neurological complications of COVID-19 like acute disseminated
encephalomyelitis with haemorrhagic compromise do not appear to
correlate with the severity of the respiratory clinical picture (Paterson
et al., 2020). Increased neurological disability among multiple sclerosis
patients was consistently associated with increased risk for worse clinical
severity and outcome of COVID-19 (Salter et al., 2021). The more we
learn about COVID-19, the more likely it is that the disease will ulti-
mately be described as a complex multi-factorial, multi-organ syndrome
of systemic breadth with underlying common pathologies of varied in-
tensities, possibly of an endothelial nature. The following sub-sections
analyse severe neurological complications of COVID-19: cerebrovascu-
lar disease and stroke, encephalopathy, encephalitis, abnormal inflam-
matory response, and direct attack of the CNS -including specific nuclei
that may be responsible for peripheral lethal outcomes of the disease.
6.1. Cerebrovascular disease
A retrospective study of 3 hospitals in Wuhan reported that 36.4% of6
the COVID-19 patients had neurological manifestations, of whom 5.7%
had acute cerebrovascular diseases, impaired consciousness (14.8%) and
encephalopathy (2.8%) (Mao et al., 2020). Of the cardiovascular injuries,
5% were acute ischaemic strokes, 0.5% venous thrombosis, and 0.5%
cerebral haemorrhages. This clinical picture appears to be reproduced in
another single-centre study (Li et al., 2020b). In another study, 2.6% of
229 non–critically ill hospitalized patients and 35.3% of 170 hospitalized
critically ill patients had thrombotic complications (Piazza and Morrow,
2020). The proportion of COVID-19 patient with stroke was found to be
1.8%, with an in-hospital mortality of 34.4%, in a multicentre study
(Fridman et al., 2020).
Strokes are a rather uncommon complication in CNS infections of
viral origin, but silent brain infarcts are likely to occur in COVID-19
patients, especially in those in ICUs. Silent infarcts are observed in
20% of otherwise healthy elderly individuals and~50% in selected series
with diabetes and/or cardiovascular comorbidities (see review in ref
(Vermeer et al., 2007)).
Massive intracerebral haemorrhage with intraventricular and sub-
arachnoid haemorrhage have been reported in elderly individuals with
COVID-19 in Iran (Sharifi-Razavi et al., 2020). Presentations of
COVID-19 in the form of acute stroke have also been reported; a retro-
spective analysis of 1916 COVID-19 patients admitted to emergency
departments in New York hospitals found that 18% had an acute
ischemic stroke (Merkler et al., 2020). The vascular damage leading to
stroke in all these cases was associated with large vessel disease (Avula
et al., 2020; Lee et al., 2020b). The marked endothelial dysregulation
appears to be at the root of the high thrombogenic activity in COVID-19
patients (Marini and Gattinoni, 2020). Remarkably, stroke can be the
first presenting clinical picture in asymptomatic young COVID-19 pa-
tients, as compiled in a meta-analysis of 125 cases from Canada, USA and
Iran (Fridman et al., 2020). These authors also found that older age, other
chronic comorbidities, and the severity of COVID-19 respiratory symp-
toms are associated with an extremely elevated (~59%) risk of death. A
systemic prothrombotic phenotype has been reported in COVID-19 pa-
tients, involving immunothrombosis in the genesis of inflammatory
microvascular thrombi containing neutrophil extracellular traps associ-
ated with platelets and fibrin, neutrophil-platelet aggregates and a
distinct neutrophil and platelet activation pattern in blood, which
changes with disease severity (Nicolai et al., 2020). In this phenotypic
classification, severely affected COVID-19 patients are characterized by
excessive platelet and neutrophil activation compared to healthy con-
trols. In most of the COVID-19 cases with complications of a cerebro-
vascular nature, the pre-existing comorbidities analysed in the preceding
section -especially hypertension and diabetes- constitute a frequent
finding, these risk factors often leading to fatal outcomes. Guidelines for
endovascular stroke treatment during the COVID-19 pandemic have
recently appeared (Ospel and Goyal, 2020).
6.2. Encephalopathy
Neurological and neuropsychiatric symptoms reported in several
cases of COVID-19 include confusion, attentional and/or memory
impairment, lethargy and delirium (Rogers et al., 2020; Kotfis et al.,
2020; Kennedy et al., 2020; Nguyen et al., 2020) and seizures (Car-
od-Artal, 2020; Lahiri and Ardila, 2020), some of which are suggestive of
encephalopathy (Espinosa et al., 2020; Filatov et al., 2020). Although
acute encephalopathy is usually a most severe complication in paediatric
viral infections (Mizuguchi et al., 2007), it can also be present in adult
patients. Acute disseminated encephalopathy is a frequent complication
of viral infections. Anatomopathological examination of 18 post-mortem
brains showed only hypoxic lesions and no signs of encephalitis or other
changes referable to the virus (Solomon et al., 2020). In contrast, similar
analyses have found parenchymal abnormalities like subcortical micro-
and macro-haemorrhages, and oedematous changes suggestive of en-
cephalopathy (Coolen et al., 2020). Glial fibrillary acidic protein and
neurofilament light chain protein, two neurochemical pathological
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blood plasma of COVID-19 patients (Kanberg et al., 2020). A study of a
cohort of 799 COVID-19 patients indicated that 113 of them (~20%)
developed hypoxic/ischemic encephalopathy (Chen et al., 2020c). A
recent study of 43 patients with COVID-19-related neurological disorders
lists encephalopathies with delirium and psychosis and no MRI or CSF
abnormalities as the leading finding (29/43 cases) (Paterson et al.,
2020).
Acute disseminated encephalomyelitis is usually a post-infectious
syndrome characterized by perivenous oedema, demyelination and
macrophage-lymphocyte infiltration, and has been observed in other
viroses like influenza associated with intracerebral cytokine release
syndrome and disruption of the BBB (Rossi, 2008). A recent case report
illustrates the lesions revealed in the necropsy of a COVID-19 patient who
presented a vascular and acute disseminated encephalomyelitis. The le-
sions resembled both vascular and demyelinating aetiologies. Haemor-
rhagic white matter lesions were observed throughout the cerebral
hemispheres with surrounding axonal injury and macrophages. Rare
neocortical micro-infarcts were also present (Reichard et al., 2020). A
possible link between the pulmonary localization of SARS-CoV-2 and
encephalomyelitic complications of COVID-19 has recently been postu-
lated (Alharthy et al., 2020).
Neurological complications are more common in older patients with
comorbidities, particularly hypertension, who presented less typical
symptoms and exhibited the more severe forms of the disease (45.5%)
compared to patients with milder presentations (30.2%) and more
typical symptoms like fever and cough (Mao et al., 2020). Intracerebral
haemorrhages constitute a severe complication of hypertensive patients,
particularly elderly patients. In COVID-19 intracerebral haemorrhages
are rare; only three cases out of 1200 hospital admissions in Russia were
recently reported (Pavlov et al., 2020). Encephalopathies as complica-
tions of COVID-19 patients without apparent penetration of the virus in
the brain parenchyma have been reported (Espinosa et al., 2020; Filatov
et al., 2020), and a more rare viral penetration of the brain stem has also
been documented (Li et al., 2020c).
The auto-amplifying, hyper-production of cytokines characteristic of
the cytokine release syndrome is a complicating factor in acute enceph-
alopathies accompanied by vasogenic brain oedema, such as is found in
Reye-like syndrome, haemorrhagic shock, encephalopathy syndrome,
and acute necrotizing encephalopathy (Mizuguchi et al., 2007). An acute
haemorrhagic necrotizing encephalopathy with bilateral involvement of
the thalami and temporal lobes has recently been reported in a female
COVID-19 patient (Poyiadji et al., 2020). This type of encephalopathy is a
rare complication of influenza or other viral infections with disruption of
the BBB but without direct viral infection.
6.3. Encephalitis
In general, acute encephalitis of infectious or immune causes (or
both) is most common in children but is also observed in adults and may
conduce to acute encephalopathy, which in severe cases has a high
mortality. Encephalitis produced by SARS-CoV infection was reported
during the SARS epidemic, associated with tonic-clonic convulsions (Lau
et al., 2004) or intractable seizures (Barcelo-Coblijn et al., 2003). A case
of meningitis and encephalitis in a 24-year old male was reported in
Japan. The acute case, accompanied by convulsions and unconscious-
ness, was diagnosed as aseptic encephalitis. SARS-CoV-2 RNA was found
in the cerebrospinal fluid (Moriguchi et al., 2020). Other cases of en-
cephalitis have now been reported (Ye et al., 2020).
In investigating the likely sources of encephalitis, one should focus
attention on those organs that are susceptible to and/or have high ca-
pacity to produce virions; one such niche is the intestinal tract. A meta-
analysis indicates 12% of COVID-19 patients manifest gastrointestinal
symptoms, including diarrhoea, nausea or vomiting, and 45% test posi-
tive for SARS-CoV-2 in faeces (Parasa et al., 2020). Interestingly, among
58 COVID-19 positive children in the U.K., 52% presented diarrhoea and7
53% abdominal pain and serious cardiovascular signs that led to the
diagnosis of paediatric inflammatory multisystem syndrome temporally
associated with SARS-CoV-2 (Whittaker et al., 2020). The enterocyte
appears to be prone to infection because of its high expression of ACE2
and TMPRSS2 (Ziegler et al., 2020), and has been shown to be extremely
efficacious at replicating and shedding SARS-CoV-2 virions. Additionally,
enterocytes have a strong interferon type-II response and exacerbated
cytokine responses (Lamers et al., 2020; Stanifer et al., 2020). The gene
coding for the viral receptor, ACE2, is a human interferon-stimulated
gene expressed, among other tissues, in ileal absorptive enterocytes
(Ziegler et al., 2020). The affectation of the gastrointestinal tract includes
the oesophagus; bleeding caused by SARS-CoV-2 infection has been re-
ported (Li et al., 2020d). The mRNA transcriptomic profiling studies
finding highest expression levels of ACE2 in intestinal enterocytes, and
the observation that ~60% of ileal enterocytes express the enzyme, lends
support to the possible intestinal source of SARS-CoV-2 virions (see Fig. 2
below).
A recent study using a murine model of COVID-19 found SARS-CoV-2
in the brain parenchyma of human ACE2-carrying transgenic mice. Some
of these mouse brains exhibited a mutation, C23525T (H644Y), in the S1
region of the spike glycoprotein gene (Jiang et al., 2020).
6.4. Direct attack of CNS and cardiorespiratory nuclei by SARS-CoV-2
The shortest possible route for secondary infection of the CNS
following primary attack of the nasal epithelium is the anterograde
pathway from the olfactory mucosa via olfactory nerve to reach the ol-
factory bulb, a path that has been extensively discussed at the hypo-
thetical level in the context of COVID-19, although there is still no firm
evidence that the virus follows this route (see review in Barrantes,
2020b). An alternative route following primary attack of the nasal mu-
cosa was early postulated for the vesicular stomatitis virus infection in
infant rats, whereby the virus could be transported from the olfactory
epithelium to the reticular core neurons in the median raphe, the ventral
and horizontal diagonal band and the locus coeruleus (Mohammed et al.,
1993). The hypothesis was recently reformulated in the context of
COVID-19 (Li et al., 2020c).
CoVs have been reported to follow neural routes other than those
originating in the nasal mucosa, e.g. synaptic routes from mechano- and
chemo-receptors in the lower respiratory airways and lungs to ultimately
reach the medulla oblongata (Li et al., 2020c; Harberts et al., 2011).
Among other CNS localizations, ACE2 is found in the brainstem cardio-
respiratory nuclei (Xu et al., 2011; Doobay et al., 2007). These routes and
receptor localizations provide an explanation for two associated phe-
nomena of different severity: 1) the paradoxical “happy hypoxia” syn-
drome, i.e. the remarkably low blood O2 levels in some COVID-19
patients and 2) the possibility that death by respiratory failure may in
fact be due to a central cause – failure of the cardiorespiratory centres in
the brain stem- rather than the atypical “CARDS” pulmonary complica-
tions. A study of 32 COVID-19 necropsies showed SARS-CoV-2 RNA in
the respiratory and cardiovascular regulatory centres in the medulla
oblongata (Meinhardt et al., 2021).
Another hypothetical affectation of a CNS nucleus postulates infec-
tion of the oropharynx, centripetal virus migration along the facial and
the vagus nerves, up to the nucleus tractus solitarius. Inflammation of this
nucleus is further suggested to be responsible, together with a defective
hypothalamic-pituitary-adrenal axis, for the abnormal cytokine produc-
tion (Ur and Verma, 2020).
7. Dysregulated inflammatory responses in COVID-19
7.1. The pro-inflammatory cytokine release syndrome and the key role of
interleukins
In the CNS, low levels of interleukin (IL) 6 (IL-6) produced by glial
cells have been associated with physiological regulation of synaptic
Fig. 2. The intestinal tract offers SARS-CoV-2
multiple entry points and routes. Various types
of epithelial cells are found in the intestinal
epithelial lining. Enterocytes are by far the most
abundant, and they express higher amounts of
ACE2 than the pulmonary alveolar cells (Xu et al.,
2020b) and also express higher amounts of
TMPRSS4, whereas secretory cells like the goblet
cells express more TMPRSS2, its isoform (Zang
et al., 2020). These two proteases also enhance
membrane fusion, facilitating virion entry into
the cells by endocytosis (arrow on apical enter-
ocyte plasmalemma) through a yet uncharac-
terized mechanism. SARS-CoV-2 replicates most
efficaciously in the enterocyte, and exocytic
shedding can occur from the apical and/or the
basal membrane (red arrow). Fluorescent-la-
belled SARS-CoV-2 particles are mostly found in
mature villous absorptive enterocytes and to a
lesser extent in undifferentiated stems cells (Zang
et al., 2020). Enteroendocrine cells (shown in
purple) exhibit lower expression levels of ACE2
and TMPRSS2/4. Once in the submucosa
SARS-CoV-2 virions can find their way to the
capillaries, also rich in ACE2 in their endothelial
cells and pericytes (depicted in green in the
lower-right corner), to reach the general circula-
tion. (For interpretation of the references to
colour in this figure legend, the reader is referred
to the Web version of this article.)
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cognitive functions (Yirmiya and Goshen, 2011). In contrast, elevated
levels of IL-6 are observed in several neurodegenerative and psychiatric
diseases (Gruol, 2015). IL-6 is also considered to be a “master player” in
the pro-inflammatory cytokine family, inducing the expression of a va-
riety of proteins involved in acute inflammation (Uciechowski and
Dempke, 2020). Neuroinflammation can be envisaged as the reactive
response of the CNS to altered homeostasis observed under a wide
spectrum of pathological conditions, either systemic and/or affecting the
CNS, including infectious diseases (Ransohoff et al., 2015). Viral in-
fections can also lead to a massive, disproportionate, or uncontrolled
systemic syndrome consisting of pro-inflammatory cytokine production
(hypercytokinemia) and release -the cytokine release syndrome (Behrens
and Koretzky, 2017). Some CoVs have been reported to induce this
syndrome. In SARS, this is associated with the hyperproduction of IL-1β,
IL-6, IL-12 A, interferon-γ, interferon-γ inducible protein 10 (IP10) and
MCP1. In MERS, augmentation of TNF, IL-15, IFN and IL-17. A has been
reported (Channappanavar and Perlman, 2017). These CoV-associated
immunological profiles led to the suggestion that SARS-CoV-2 could
also trigger a hyper-inflammatory cytokine release syndrome (Mehta
et al., 2020). Indeed, early reports indicated that some COVID-19 pa-
tients exhibited an abnormal cytokine profile (Huang et al., 2020) asso-
ciated with disease severity and respiratory failure in particular (Moore
and June 2020). The profile involved macrophage activation and
increased levels of IL-2, IL-2R, IL-7, IL-8, IL-9, IL-10, granulocyte colony
stimulating factor, IP-10, monocyte chemoattractant protein 1, macro-
phage inflammatory protein 1-α, tumour necrosis factor-α (Huang et al.,
2020) and elevated ferritin (Ruan et al., 2020). The latter is a clinical
laboratory predictor of possible fatal outcome. IL-1β and tumour necrosis
factor activate glucuronidases that enzymatically digest the complex and
extensive glycocalyx barrier covering the endoluminal endothelial cell
surface, and upregulate hyaluronic acid synthase 2, an enzyme that in-
creases hyaluronic acid deposition in the extracellular space, thus
contributing to water and electrolyte retention and oedema (Teuwen
et al., 2020). This syndrome is particularly dangerous in older patients
who have a basal “inflammaging” (increased basal inflammation) status8
and multi-organ accumulation of senescent cells (Akbar and Gilroy,
2020) that may predispose them to a dysfunctional immune response.
This coincides with the decline in macrophage activity, naïve T cell
production and effector memory T cell competence in the elderly (Li
et al., 2019). Along these lines, a recent study indicates that when ac-
counting for cofounding factors, the cytokine storm is a relatively rare
(3–4%) event among COVID-19 patients, affecting predominantly elderly
patients who require ventilatory assistance (Mudd et al., 2020).
The hyper-inflammatory syndrome in COVID-19 has been described
to follow the trans-route (Moore and June 2020), mainly involving the
pro-inflammatory IL-6 family. IL-6 levels in plasma were found to be a
strong predictive marker of upcoming respiratory failure in hospitalized
COVID-19 patients (Herold et al., 2020).
Recent transcriptome analyses addressing characterization of host
cell responses to SARS-CoV-2 infection revealed unexpected differences
between the responses to this virus and responses to other respiratory
viruses having similar tropism. Using a human adenocarcinoma epithe-
lial cell assay, the study disclosed two interesting findings: despite having
undetectable levels of ACE2 and the TMPRSS2 protease, a) the alveolar
epithelial cells supported virion replication and b) SARS-CoV-2 replica-
tion produced a muted antiviral response, with unusually low production
of interferons and higher than normal levels of IL-6 (Blanco-Melo et al.,
2020). The in vitro assay was validated by infection of ferrets with
SARS-CoV-2; the animals showed similar muted responses, with tran-
scriptional profiles showing diminished cytokine responses.
Auto-antibodies against type I interferons have been observed in
patients with life-threatening cases of COVID-19 (Bastard et al., 2020).
Activated immune cell infiltration of the brain parenchyma may include,
however, the Ly6Glo subset of neutrophil-like cells with the capacity to
induce CNS neural regeneration (Sas et al., 2020).
As the pandemic extends in time, the lifetime of cytokine responses in
the disease is beginning to be characterized. Inflammatory cytokines
persist for several weeks in the cerebrospinal fluid of oncological patients
with neurological manifestations of COVID-19 after SARS-CoV-2 infec-
tion (Remsik et al., 2021).
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production
A recent report has identified a carbohydrate metabolic pathway
required for activating influenza virus-induced cytokine release syn-
drome (Wang et al., 2020b). The transcription factor interferon regula-
tory factor 5 (IRF5) is required to induce the pro-inflammatory cytokine
production observed in influenza virus infection. IRF5-induced inflam-
matory response enhances glucose metabolism because more energy is
required by immune cells for the cytokine response and because the virus
requires carbohydrates for replication. The hexosamine biosynthetic
pathway is the commonmetabolic requirement for both processes (Wang
et al., 2020b). These findings raise the possibility that a similar process
occurs in the cytokine pro-inflammatory syndrome associated with other
viral infections, including COVID-19. A recent study conducted on 1122
COVID-19 patients in the United States found that those with diabetes or
hyperglycaemia have a four-fold greater mortality than those without
these comorbidities. The IRF5 cascade also induces pro-inflammatory
cytokine production that eventually leads to the cytokine release
syndrome.
The effect of aging on the immune response has been analysed in a
recent viewpoint article (Akbar and Gilroy, 2020). Briefly, the combi-
nation of a basal inflammatory status in older individuals and
multi-organ accumulation of senescent cells would be key predis-
posing/exacerbating factors for dysregulated immune responses in
COVID-19 elderly patients. Thus, although hyper-inflammatory re-
sponses have dominated recent views about the immune response in
COVID-19, this and other findings suggest that insufficient immune re-
sponses may also be operative. For example, the non-structural protein
nsp1 from SARS-CoV-2 effectively induces a nearly complete shutdown
of the host protein translation upon binding to the 40S small ribosomal
subunit, thereby blocking innate immune responses that would otherwise
facilitate clearance of the infection (Thoms et al., 2020).
Recent immune-metabolic profiling has identified populations of T
cells and myeloid cells with unique gene programmes and metabolic
profiles linked to mitochondrial dysfunction and apoptosis and which
correlate with lymphopenia and COVID-19 severity (Thompson et al.,
2021). CD4þ T cells, CD8þ T cells, and neutralizing antibodies synergi-
cally contribute to control SARS-CoV-2 infection (Sette and Crotty,
2021).
7.3. Immune profile as a marker of COVID-19 severity
One important question is what marks the transition from the mild-to-
moderate to the severe (10–20%) forms of the disease (Jain and Yuan,
2020). Single-cell RNA sequencing and single-cell proteomics of blood
mononuclear cells showed changes in immune cell composition and
activation over time. In one study, HLA-DRhighCD11chigh (human
leukocyte antigen -DR isotype) inflammatory monocytes with an
interferon-stimulated gene signature were found to be elevated in mild
COVID-19. The severe form of the disease showed neutrophil precursor
cells, pointing to emergency myelopoiesis, dysfunctional mature neu-
trophils expressing PD-L1 and abnormal oxidative response, and
HLA-DRlow monocytes, indicating marked affectation of the myeloid
lineage and resulting in continuous tissue inflammation and ineffective
host defence (Schulte-Schrepping et al., 2020). In a second study, the
disappearance of non-classical CD14lowCD16high monocytes and accu-
mulation of HLA-DRlow were accompanied by massive release of cal-
protectin (Silvin et al., 2020). These authors suggest the use of flow
cytometry assays to detect decreases in non-classical monocytes and
predict the evolution of COVID-19 cases. Both survivors and
non-survivors of severe COVID-19 develop robust IgM and IgA responses
accompanied by defective Fcγ receptor binding and Fc effector activity,
indicating deficient humoral immunity; moderate COVID-19 patients
develop sluggish delayed responses that eventually mature (Zohar et al.,
2020).9
A multi-omics analysis of blood plasma collected from COVID-19
patients during the first week of infection following diagnosis revealed
changes in the immune cell repertoire, increases in inflammatory
markers and loss of metabolites and metabolic processes as the disease
evolved from mild to moderate severity (Su et al., 2020). A tran-
scriptomics study characterized the single-cell RNA profile of peripheral
mononuclear cells of COVID-19 patients, revealing defective antigen
presentation in monocytes and high interferon responsiveness in lym-
phocytes, and suppression of genes involved in cytotoxic activity in both
NK and CD8 lymphocytes, thus explaining the reduced viral clearance of
severe COVID-19 patients (Yao et al., 2020). Single-cell RNA-sequencing
of host factors has also disclosed changes in cholesterol biosynthesis in
the disease: increased cholesterol synthesis correlates with SARS-CoV-2
resistance (Daniloski et al., 2020). Another study from the same au-
thors surveyed >20,000 potential anti-SARS-CoV-2 compounds, identi-
fying some that induced cholesterol biosynthesis as potential viral
inhibitors.
As we see, the immune response in COVID-19 patients is highly het-
erogeneous, particularly in hospitalized patients with severe forms, with
some patients displaying robust CD8 T cell and/or CD4 T cell activation
and proliferation, while ~20% of patients exhibit minimal responses
(Mathew et al., 2020); the former group probably corresponds to those
patients presenting high tissular viral load in autopsies (Xu et al., 2020a).
The immune response is doubly anomalous: SARS-CoV-2 replication
produces in some cases a muted antiviral response, with negligible pro-
duction of interferon type-I and II in response to the virus infection, but
also pathologically elevated cytokine levels - IL-6 in particular (Blan-
co-Melo et al., 2020). This configures a severely abnormal innate anti-
viral response coupled to the dysregulated inflammatory cytokine
production discussed in previous sections. The diagnostic signature
recently associated with this condition is configured by increased IP-10,
IL-10 and IL-6, a triad that anticipates subsequent clinical progression
(Laing et al., 2020). According to these authors, this triad of
pro-inflammatory markers constitutes a signature that predicts length of
hospitalization; its use is recommended for diagnostic purposes such as
early risk-based stratification of patients. They also suggest targeting the
triad as a therapeutic strategy that may contribute to the success of
dexamethasone treatment. Peripheral blood neutrophil profiling is also
emerging as a predictive diagnosis of disease course and its use is sug-
gested for patient risk stratification (Aschenbrenner et al., 2021).
8. A unifying hypothesis of SARS-CoV-2 affectation of the CNS
As SARS-CoV-2 paths in the human organism are dissected and al-
terations compromising different organs are increasingly disclosed, the
casuistic of neuropathological findings in necropsies of COVID-19 pa-
tients reveal that the most common findings are neuroinflammatory al-
terations of the brain stem (Matschke et al., 2020). The notion of
common underlying pathophysiological mechanisms and multiple target
organs is gaining strength. COVID-19 symptomatology obeys the singu-
larities of the different organs under viral attack, but the conjunction of
abnormal immune responses, coagulopathies involving alteration of the
coagulation factors, platelet activation and stasis constitute a constella-
tion of factors pointing to virus-induced endothelial bed damage leading
to micro-thromboembolism as a common noxa. Genome-wide associa-
tion studies (GWAS) are beginning to disclose genetic factors associated
with disease severity and life-threatening COVID-19, mostly involving
two key immune signalling pathways: interferon-mediated antiviral sig-
nalling and chemokine-mediated inflammatory signalling (McCoy et al.,
2020). Other genes include ethnicity and specific genes like SLC6A20,
LZTFL1, CCR9, FYCO1, CXCR6, XCR1 ABO, FOXP4 or CCR2 (Ellinghaus
et al., 2020), and gene clusters near the gene coding for tyrosine kinase 2
(TYK2), within the gene encoding dipeptidyl peptidase 9 (DPP9), or the
interferon receptor gene IFNAR2 (Pairo-Castineira et al., 2020).
This leads us to formulate a unifying hypothesis of SARS-CoV-2 severe
affectation of the CNS. Analysis of the possible virus entry points makes
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to the brain, the local infection may not suffice to result in a robust
systemic virion shedding and ensuing viremia (Barrantes, 2020a, 2020b).
In fact, only two primary entry points fulfil the requisite massive supply
of virions to affect the CNS in a severe form: the pulmonary and the in-
testinal mucosae, the latter with twice the surface and expressing higher
amounts of ACE2 than the pulmonary lining (Xu et al., 2020b). In this
final section I bring together the two requirements, namely the enteric
entry point and the damaged endothelial cell to elaborate on a unifying
hypothesis linking the gastrointestinal tract primary infection to the CNS
affectation.
8.1. The gastrointestinal tract-brain axis
The digestive tract is a key SARS-CoV-2 entry point and various routes
emanating from the enteric tract can be followed by the virions to reach
the CNS (Barrantes, 2020b). Clinical studies have underscored the
importance of this route (Jin et al., 2020; Parasa et al., 2020; Zhou et al.,
2020b; Ding and Liang, 2020; Trottein and Sokol, 2020) and proteomic
and immunohistochemical studies have corroborated several aspects of
these hypotheses, providing evidence for robust expression of receptors
and co-receptors in enterocytes as well as in neurons and glial cells of the
enteric nervous system (Deffner et al., 2020; Briguglio et al., 2020; Liang
et al., 2020c) and distinct stem cell clusters in the proximal and distal
small intestine (Liang et al., 2020c).
A cryo-EM study has solved the structure of the full-length human
ACE2 with or without the receptor-binding domain (RBD) of the SARS-
CoV-2 spike (S) protein in the presence of a neutral amino acid trans-
porter, BAT1 (Yan et al., 2020). BAT1 is the major luminal
sodium-dependent neutral amino acid transporter of the small intestine
and kidney proximal tubule. Interestingly, to be expressed in the small
intestine, BAT1 critically requires to be associated with collectrin
(Tmem27), a protein homologous to the transmembrane region of ACE2
(Camargo et al., 2009). ACE2 is essential for the intestinal uptake of the
amino acid tryptophan. As is well known, this amino acid is the precursor
of 5-hydroxytryptamine, the neurotransmitter serotonin. ACE2 is also
necessary for exercise-dependent modulation of pro-mitotic adult neu-
rogenesis in rodent adult hippocampus (Klempin et al., 2018). These are
two examples of the multiple functions displayed by the SARS-CoV-2
receptor in its pleotropic roles in these two organs and the possible
interrelationship via intestine-brain neural or circulatory system con-
nections (see Fig. 2 below).
The high receptor capacity of the entericmucosae, especially that lining
the duodenum and ileum, with expression of ACE2 and the two isoforms of
the serine protease TMRSS2 and TMPRSS4 (Grasselli et al., 2020) (higher
than that in the bronchoalveolar epithelium (Xu et al., 2020b)), together
with the extensive surface area of the intestinal mucosa (ca. 250 m2) make
the intestinal tract a massive source of virion uptake, replication, and
shedding that can be fed into the intestinal lumen or the bloodstream, and
reach elevated viral titres, inducing the production of excess levels of
pro-inflammatory cytokines. Clinical presentations of intestinal disease in
COVID-19 are increasingly being reported (Jin et al., 2020; Parasa et al.,
2020) and pathological findings of intestinal damage are observed in 45%
of COVID-19 necropsies (Bryce et al., 2020). It is currently not known to
what extent the microbiota of the gastrointestinal tract plays a role in the
infectious mechanism or whether chronic inflammatory bowel conditions
constitute a risk factor (Zhou et al., 2020b). The inflammatory status may
also apply to the endothelial cells of the intestinal microcirculation capil-
laries. Once these barriers are surpassed, the virions in the circulatory
stream can reach any organ. A recent in vitro study using human intestinal
epithelial cells showed the very efficient infection of these cells by
SARS-CoV-2 (Stanifer et al., 2020). The virions are rapidly inactivated by a
medium resembling the content of the colon, leading to the suggestion that
the viral mRNA that transits through the large intestine is not infectious
(Zang et al., 2020), thus making the faecal-oral transmission (Ding and
Liang, 2020) less tenable for SARS-CoV-2.10As schematically shown in Fig. 2, virions can be either endocytosed by
enterocytes or find their way between epithelial intercellular junctions
and subsequently the endothelial gaps (Pober and Sessa, 2007), to reach
the submucosal capillary network and the general circulation via the
hepatic portal system. SARS-CoV has been reported to enter cells in
complex with ACE2 via a pH-, clathrin- and caveolin1-dependent endo-
cytic process which apparently occurs in cholesterol/sphingolipid-rich
membrane lipid domains (the so-called “lipid rafts”) (Wang et al.,
2008). More recent experimental evidence indicates that SARS-CoV-2
follows a specific endocytic pathway, namely the clathrin and
dynamin-independent, pH-dependent CLIC/GEEC endocytic pathway.
Endosomal acidification inhibitors like BafilomycinA1 and NH4Cl, which
inhibit this pathway, strongly block viral S protein uptake (Prabhakara
et al., 2020).
I have suggested the enteric nervous system as an alternative centripetal
viral route exploiting the submucosal or the myenteric plexuses (Bar-
rantes, 2020b), a hypothesis that has subsequently found experimental
support (Deffner et al., 2020). SARS-CoV-2 infection of the these plexuses
and neurons may constitute intermediate stations in the virus track to the
CNS, as is the case with the neurotropic varicella zoster virus (Gershon
and Gershon, 2013). SARS-CoV-2 might also undergo latency in neurons,
as is observed with the varicella virus. The human dorsal root ganglion
(DRG) sympathetic neuron expresses the ACE2 gene (Ray et al., 2018)
(Shiers et al., 2020) as well as theMRGPRD andNppb genes, the former of
which is selectively expressed in a subset of nociceptive receptors with
peripheral nerve branching in colon (Hockley et al., 2019) or meninges
(von Buchholtz et al., 2020) together with the ACE2 gene (Shiers et al.,
2020). The centripetal retrograde pathway to the CNS followed by the
virus would be even more direct if infection involved the DRG neuron
(Barrantes, 2020b; De Virgiliis and Di Giovanni, 2020).
8.1.1. The blood-brain barrier (BBB) and endothelial integrity
The BBB is a multicellular stratified natural fence composed of brain
capillary endothelial cells surrounded by pericytes, astrocyte end-feet
and the extracellular basal lamina. Permeation of the barrier is severely
restricted to all but a few small hydrophobic molecules, although
permeability is not linearly related to the size of the solutes present in the
blood stream (see reviews in (Abbott et al., 2010; Zlokovic, 2008; Rus-
tenhoven and Kipnis, 2019)). It is increasingly being appreciated that the
barrier is not purely anatomical, but also involves immune, electrolyte,
water transport, and metabolic barriers (Begley, 2004). Because of the
BBB, the brain as an organ is effectively isolated from the rest of the
body’s economy. The process of acquiring such a sophisticated barrier in
the course of phylogenetic evolution is conjectured to derive from the
need to isolate neuronal excitability from ionic fluxes stemming from
blood plasma (Abbott, 2005; Obermeier et al., 2016).
The endothelium fulfils multiple physiological roles, acting as an
immunological barrier and regulating vascular permeability through its
semi-permeable interface. The vascular endothelium growth factor
(VEGF) is a major protagonist in endothelial physiology (Li et al., 2020e).
Upon activation of VEGF-A receptor, a downstream metabolic cascade
involving cadherin phosphorylation participates in the regulation of
endothelial permeability. Endothelial cells perform autocrine and para-
crine functions, producing angiogenic factors as well as vasoconstrictor
factors like endothelin-1 to regulate vascular tone together with vaso-
dilatory mechanisms mediated by nitric oxide and ACE2. The brain
capillary bed is in relatively close topographic contact with glial and
nerve cells, particularly astroglial endings surrounding the pericytes and
endothelial cells (Fig. 3).
Direct passage of virions into the brain parenchyma could in principle
occur in areas rich in fenestrated capillaries, i.e. lacking a proper BBB and
thus allowing exchange between the blood and the cerebrospinal fluid, as
is the case with the so-called circumventricular organs in the vicinity of
the 3rd and 4th ventricles (Xu et al., 2011). Another possible mechanism
for crossing the BBB is via macrophages, as is the case with the HIV-1
virus (Barker and Vaidya, 2020).
Fig. 3. The key dysfunctional unit in
brain: the capillary endothelial cell-
pericyte. Upper figure: SARS-CoV-2 vi-
rions (blue particles) have been found in
infected endothelial cells in necropsy
samples of frontal cerebral cortex from a
COVID-19 patient (Paniz-Mondolfi et al.,
2020). Mechanisms for viral crossing of
the BBB include disruption of the tight
junctions sealing contiguous endothelial
cells (Pober and Sessa, 2007), trans-
cytosis (Rhea et al., 2021) and/or
endocytic internalization of the virus
upon binding to ACE2. Other receptors
present in brain vasculature have been
invoked (Cantuti-Castelvetri et al., 2020;
Daly et al., 2020). The viral load into the
blood stream is highly variable (Zheng
et al., 2020). Pericytes (Brann et al.,
2020) and astrocytes (Chen et al.,
2020b; Xia and Lazartigues, 2008)
possess ACE2 receptor capacity that
could further spread the virus in the
brain parenchyma once the BBB has
been surpassed. SARS-CoV-2 S1 protein
has recently been shown to trespass the
BBB in a murine model, reaching all re-
gions of the brain (Rhea et al., 2021).
Lower figure: Another salient patholog-
ical aspect of endothelial dysfunction is
related to the overexpression of
astrocyte-derived cytokine CXCL1 and
neutrophil, activated immune cell, and
monocyte infiltration into the brain.
These manifestations are observed in
herpes simplex (HSV-1) infection asso-
ciated with viral encephalitis. The che-
mokine (C-X-C motif) ligand 1 (CXCL1)
is produced by astrocytes in response to
HSV-1 and by astrocytes and neurons in
response to IL-1α (Michael et al., 2020)
and forms part of the SARS-CoV-2
hyper-neuroinflammatory response.
(For interpretation of the references to
colour in this figure legend, the reader is
referred to the Web version of this
article.)
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thromboembolic and pro-inflammatory reactions
8.2.1. The vascular endothelial growth factor cascade
When IL-6 binds to the soluble variant of its receptor, the latter forms
a complex with the signal-transducing molecule gp130, present at the
surface of essentially all cells in the organism. This complex then acti-
vates the release of various factors, including platelet-secreted vascular
endothelial growth factor (VEGF) and monocyte chemoattractant
protein-1, inhibiting E-cadherin in endothelial cells (Moore and June
2020; Teuwen et al., 2020). This, in turn, loosens the tight junctions
between endothelial cells (“endothelial gaps”) (Pober and Sessa, 2007),
leading to increased vascular permeability and leakage, and possibly
precipitating the cytokine release syndrome (Behrens and Koretzky,
2017) in brain. Another implication of VEGF in COVID-19 is its reported
ability to activate the neuropilin-1 receptor, a process that increases
SARS-CoV-2 spike protein engagement. Indeed, VEGF-A is not only an
angiogenic growth factor but is also a trigger that activates neuronal11firing related to pain sensing. Neuropilins are expressed on normal blood
and lymphatic endothelial cells, playing roles in the formation of blood
and lymphatic vascular networks during angiogenesis. They act as
co-receptors of VEGF receptors and support angiogenic signalling
(Alghamdi et al., 2020). Given the ability of the SARS-CoV-2 spike pro-
tein, but not that of SARS-CoV or MERS-CoV, to bind to the b1b2 domain
of the neuropilin-1 receptor (Cantuti-Castelvetri et al., 2020; Daly et al.,
2020), SARS-CoV-2 infection might interfere with VEGF-A/neuropilin-1
receptor pain sensing (Moutal et al., 2020).
8.2.2. The bradykinin cascade
Pro-inflammatory mechanisms also affect the endothelial cells, which
intervene directly and indirectly in coagulation. Another abnormal
mechanism intervening in endothelial cells is the bradykinin B1 cascade,
initiated by activation of bradykinin B1 receptors present in the endo-
thelial cells. Upregulated by pro-inflammatory cytokines (van de Veer-
donk et al., 2020), this cascade could also be operative in brain. ACE2 is
required to inactivate des-Arg9 bradykinin, the potent endogenous ligand
F.J. Barrantes Brain, Behavior, & Immunity - Health 14 (2021) 100251of B1 receptors. If ACE2 is “knocked-out” by SARS-CoV-2 binding, local
vascular leakage could ensue, leading to angioedema. Importantly, direct
experimental evidence of the presence of SARS-CoV-2 in the endothelium
of COVID-19 patients demonstrating endothelial viral infection and
diffuse lymphocytic endotheliitis is now available (Varga et al., 2020).
Under normal conditions, endothelial nitric oxide synthase releases
nitric oxide, with its vasodilator and anti-thrombotic effects; one of the
hallmarks of endothelial dysfunction in COVID-19 is the diminished ac-
tivity of this enzyme, with concomitant nitric oxide deficiency (Green,
2020). Endothelial dysfunction shifts the delicate equilibrium of endo-
thelial homeostasis towards reduced vasodilation, a pro-inflammatory
status, and pro-thrombotic conditions, i.e. conditions akin to those
found in endotheliitis. Inflammation, an early protective mechanism
against diverse noxa, is tightly regulated to provide a balanced response
(see recent review by (Weavers and Martin, 2020). The multimolecular
protein complexes called inflammasomes play an important role in this
mechanism; upon activation, the enzyme caspase-1 cleaves the inactive
cytokine precursors pro-IL-1β and pro-IL-18 to produce their active forms
(Seoane et al., 2020).
There is increasing evidence that in COVID-19, adhesion molecules
are upregulated, cytokines such as macrophage chemoattractant peptide-
1 are generated, inflammatory cells infiltrate the brain parenchyma
(Fig. 3), and plasminogen activator inhibitor-1 contributes to the in-
flammatory response and pro-thrombotic status. SARS-CoV-2 in complex
with ACE2 leads to depletion of the receptor in infected cells, lowering
the level of angiotensin 1-7 and increasing the level of angiotensin II, the
latter further inducing vasoconstriction and pro-inflammatory and pro-
coagulant effects (Abassi et al., 2020). Native anticoagulant mecha-
nisms such as those involving protein C, tissue factor pathway inhibitor
(TFPI) or antithrombin are often altered in COVID-19. Spliced isoforms of
TFPI are expressed differentially by endothelial cells (TFPIβ) and plate-
lets (TFPIα) (Mast, 2016). The activated form of the pro-enzyme serine
protease protein C, i.e. activated protein C, displays potent anti-coagulant
and anti-thrombotic activities (Griffin et al., 2018). The dysfunctional
status of pulmonary endothelial cells and biomarkers in COVID-19 is
reviewed in ref. (Kaur et al., 2020).
Although many of the micro-vasculopathy alterations in COVID-19
are centred on the endothelial cell, pericytes are also affected, particu-
larly in the pulmonary parenchyma, where post-mortem studies have
revealed apoptosis and lower numbers of pericytes (Cardot-Leccia et al.,
2020).
8.3. Coagulopathies
Coagulation abnormalities affect endothelial functions, looping feed-
back mechanisms that lead to mutual activation and amplification of
both pathologies. Plasma proteins intervening in the acute phase of
coagulation and fibrinolysis are elevated in inflammation, whereas
endogenous natural anticoagulatory mechanisms are inhibited (Connors
and Levy, 2020; Arachchillage and Laffan, 2020). Pro-inflammatory cy-
tokines further induce changes in the plasmalemma of endothelial cells
and circulating blood cells towards a coagulant-prone status, including
thrombin formation within small blood vessels, configuring a thrombotic
microangiopathy that is beginning to be corroborated in COVID-19
necropsies (Meinhardt et al., 2021). Post-mortem studies of COVID-19
patients found that neutrophil activator marker CD177 was highly
upregulated in neutrophils in microvascular thrombi of patients having
severe forms of COVID-19, whereas less severe cases showed lesser levels
of the activator. The authors also found a highly activated subpopulation
of platelets (Nicolai et al., 2020). Post-mortem anatomopathological
examination of COVID-19 patients in Germany showed that the cause of
death of older patients (>65 years-old) was cardiorespiratory failure,
whereas patients younger than 65 years died either of massive intra-
cranial haemorrhage or pulmonary embolism, consistent with the coa-
gulopathy increasingly found in COVID-19 (von Weyhern et al., 2020).
Clinically, the abnormal coagulant-pro status is manifested in prolonged12prothrombin time and is accompanied by mild thrombocytopenia.
D-dimer is higher in deceased patients, suggesting the association of
coagulopathies with poor prognosis (Wu et al., 2020b; Tang et al., 2020;
Paterson et al., 2020; Marini and Gattinoni, 2020; Arachchillage and
Laffan, 2020; Shi et al., 2020; Chen et al., 2020d). The thrombotic pa-
thology involves micro- and macro-thromboses in the lungs and other
organs, including brain (Zhou et al., 2020a), with lesions of both venous
and arterial systems (Bikdeli et al., 2020; Klok et al., 2020). The latter
study conducted on 181 ICU patients showed 31% incidence of throm-
botic complications. Some of these pathologies had already been
observed with SARS patients who presented hypercoagulable status and
large artery ischemic strokes (Tsai et al., 2005). Histopathological find-
ings of intravascular fibrin thrombi in medium size arteries, arterioles
and capillaries were observed in essentially all necropsies of 67
COVID-19 individuals in New York (Bryce et al., 2020). This picture in-
cludes the CNS, where multifocal microthrombi, petechial micro-
haemorrhages, and acute infarctions were observed in 6/20 cases,
affecting the frontal, parietal or occipital lobes. A recent study using
radiolabelled spike protein unambiguously shows that the viral protein
crosses the BBB presumably by an adsorptive transcytosis mechanism
involving ACE2, reaches all regions of the brain and is partly retained by
the brain endothelial cells (Rhea et al., 2021). Recent transcriptomic
studies of necropsy samples from 144 COVID-19 patients have shown
elevated expression of cathepsin L1, rather than ACE2, in pulmonary
tissue, and stressed the multi-organ nature of the disease, with dysre-
gulation of angiogenesis, coagulation and fibrosis (Nie et al., 2021).
A further complication of thrombotic nature in COVID-19 patients,
akin to the antiphospholipid syndrome, has recently been disclosed.
Importantly, pro-thrombotic IgG and IgM autoantibodies against phos-
pholipids or phospholipid-binding proteins, like anti-cardiolipin and
anti-phosphatidyl serine, were found in 52% of hospitalized COVID-19
patients, correlating with disease severity (Zuo et al., 2020). These au-
toantibodies are known to activate endothelial cells, platelets and neu-
trophils and are usually correlated with neutrophil hyperactivity,
including the release of neutrophil remnants, the so-called extracellular
traps, adding to the pro-thrombotic status.
9. Concluding remarks
The unfolding picture of COVID-19 is increasingly revealing its
multifaceted, systemic and complex nature. Both the virus and the host
organism contribute to the complexity of the connections and epi-
phenomenological clinical forms, with numerous partnerships between
SARS-CoV-2 RNA and/or proteins and host-cell processes. Mutants of the
virus with varying infectivity, different glycan moieties masking anti-
body targets on the viral surface and risk factors like age, comorbidities
such as hypertension, cardiac or renal diseases and obesity, intermix to
produce a wide palette of clinical outcomes both at the level of the in-
dividual and the population. The emerging genetic factors, including
ethnicity and specific genes related to immune and inflammatory path-
ways, contribute to the pathogenesis and may influence the outcome of
the disease. There are still many aspects of this complex nosological
entity that remain to be elucidated and its severity in many cases and
pandemic scale warrant further investigation in years to come.
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